MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score
European Journal of Radiology · 2024
DOI: 10.1016/j.ejrad.2024.111463 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Radiology, 2024. Verfasst von Antonia M Pausch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Observer Variation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PURPOSE: To investigate inter-reader agreement, and diagnostic performance of the Prostate Imaging after Focal Ablation (PI-FAB) score applied to multiparametric MRI (mpMRI) in patients who underwent focal high-intensity focused ultrasound (HIFU) therapy for localized prostate cancer. METHODS: In this retrospective, IRB-approved, single-center study, 73 men, who underwent focal HIFU treatment and received follow-up mpMRIs with subsequent prostate biopsies, were included. The PI-FAB score was applied to follow-up MRIs at 6, 12, and 36 months post-HIFU by two radiologists with different experience levels. Inter-reader agreement was assessed using Gwet's AC1, and the diagnostic performance of the PI-FAB score was assessed in relation to histopathologic results of subsequent prostate biopsies for each reader. RESULTS: PI-FAB scores showed substantial to almost perfect inter-reader agreement (AC1: 0.80-0.95) and demonstrated high specificity (Reader 1: 90-98 %, Reader 2: 87-98 %) and NPVs (Reader 1: 91-100 %, Reader 2: 88-97 %) in ruling out residual or recurrent in-field prostate cancer post-HIFU. Sensitivity (Reader 1: ≥43 %, Reader 2: ≥14 %) and PPVs (Reader 1: ≥33 %, Reader 2: ≥14 %) were mostly relatively lower, with notable disparities between the two readers, indicating the potential influence of radiologist experience. CONCLUSIONS: The PI-FAB score provides a consistent and reliable tool for post-HIFU monitoring of prostate cancer using mpMRI. It demonstrates substantial to almost perfect inter-reader agreement and is particularly effective in excluding in-field residual or recurrent prostate cancer post-HIFU treatment. Its application can potentially enhance post-treatment patient care, emphasizing its value as a non-invasive MRI-based monitoring approach after focal ablative therapy of the prostate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland.
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Department of Urology, University Hospital Zurich, Switzerland.
- Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland. Electronic address: andreas.hoetker@usz.ch.
Zitieren
APA
Pausch, A. M., Elsner, C., Rupp, N. J., Eberli, D., & Hötker, A. M. (2024). MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. European Journal of Radiology. https://doi.org/10.1016/j.ejrad.2024.111463
Vancouver
Pausch AM, Elsner C, Rupp NJ, Eberli D, Hötker AM. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. European Journal of Radiology. 2024. doi:10.1016/j.ejrad.2024.111463
BibTeX
@article{Pausch2024,
author = {Pausch, Antonia M and Elsner, Clara and Rupp, Niels J and Eberli, Daniel and Hötker, Andreas M},
title = {MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score},
journal = {European Journal of Radiology},
year = {2024},
doi = {10.1016/j.ejrad.2024.111463}
}
EUVIMED